Page last updated: 2024-08-24

gemcitabine and Lymphoma of Mucosa-Associated Lymphoid Tissue

gemcitabine has been researched along with Lymphoma of Mucosa-Associated Lymphoid Tissue in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Cheng, Y; Dang, Q; Huang, J; Shi, W; Yang, L; Zhang, Y; Zhou, H	1
Hasanov, M; Hernandez, CMR; Konoplev, SN	1
Choi, YJ; Chung, JS; Kang, HJ; Kim, HJ; Kim, SH; Kim, SJ; Kim, WS; Lee, DH; Oh, SY; Ryoo, BY; Suh, C	1

Trials

1 trial(s) available for gemcitabine and Lymphoma of Mucosa-Associated Lymphoid Tissue

Article	Year
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Investigational new drugs, 2010, Volume: 28, Issue:2 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cooperative Behavior; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors; Treatment Outcome	2010

Article

Year

Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.

Investigational new drugs, 2010, Volume: 28, Issue:2

Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cooperative Behavior; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors; Treatment Outcome

2010

Other Studies

2 other study(ies) available for gemcitabine and Lymphoma of Mucosa-Associated Lymphoid Tissue

Article	Year
Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma. Cancer biology & therapy, 2020, 04-02, Volume: 21, Issue:4 Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Oxaliplatin; Piperidines; Prognosis; Rituximab; Vincristine	2020
Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. Blood advances, 2018, 08-14, Volume: 2, Issue:15 Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasms, Second Primary; Nivolumab; Rituximab; Syndrome	2018

Article

Year

Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.

Cancer biology & therapy, 2020, 04-02, Volume: 21, Issue:4

Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Oxaliplatin; Piperidines; Prognosis; Rituximab; Vincristine

2020

Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab.

Blood advances, 2018, 08-14, Volume: 2, Issue:15

Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasms, Second Primary; Nivolumab; Rituximab; Syndrome

2018